AbCellera Presents ABCL635 Phase 2 Data for Menopause Symptom Treatment

• AbCellera completed all 2026 pipeline priorities, advancing three additional programs into its internal pipeline.
• ABCL635 Phase 2 week-four data suggested improved efficacy versus available nonhormonal therapies for moderate-to-severe vasomotor symptoms.
• Cash balances and marketable securities exceeded $790 million, supporting more than three years of pipeline investments.
• Available government funding exceeded $100 million.
• The internal pipeline included two molecules in clinical trials and five programs in IND-enabling activities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.